Gilbert Tang M.D.
Director, Valve Disease Center
Associate Professor, Cardiothoracic Surgery,
New York Medical College
Dr. Tang received his bachelor's degree at Harvard University and MD at the University of Toronto, where he completed his residency in cardiac surgery as the Chief Resident at the Toronto General Hospital. Then he pursued an advanced fellowship at Mount Sinai Medical Center in New York focusing on complex mitral valve repair and transcatheter aortic valve replacement (TAVR) .
Dr. Tang also underwent special training in TAVR at the Leipzig Heart Center in Germany and the University of Pennsylvania. His clinical interests include surgical and catheter management of aortic and valvular heart disease, including TAVR, transcatheter mitral valve repair/replacement (TMVR, MitraClip) and thoracic endovascular aortic repair (TEVAR). Dr. Tang is a Diplomat and Fellow of the Royal College of Physicians and Surgeons of Canada.
During residency Dr. Tang obtained his Master of Science in tissue engineering at the University of Toronto and MBA at Harvard Business School. He has received numerous awards in research, education and leadership, presented at national and international meetings and published many articles and book chapters on valve surgery and stem cell therapy. He serves as a guest reviewer in several top peer-reviewed cardiovascular medical journals and as a physician proctor and consultant for medical device companies.
Since joining Westchester, Dr. Tang, through the support of the hospital and the Heart and Vascular program physicians and staff, has played a pivotal role in launching the Transcatheter Heart Program. The first TAVR procedure was performed on February 7, 2013, and the program has already had over 100 cases performed with excellent outcomes, marking one of the most successful program launches in New York City, Hudson Valley region and the country. Now, TAVR can be done routinely at Westchester with only local anesthesia and IV sedation, further improving patient outcomes and recovery.
Under the leadership of Dr. Tang, the Transcatheter Heart Program has achieved many “first” successes in the region and United States, including transcatheter aortic, mitral, tricuspid valve-in-valve replacement, and mitral valve-in-ring replacement, all performed via the groin without open surgery. The Program also offers minimally invasive approaches to repair and replace a diseased mitral valve with severe stenosis or regurgitation without open heart surgery, performing transcatheter mitral valve repair with a device called the “MitraClip”.
Dr. Tang and the advanced cardiac imaging group at Westchester Medical Center have also pioneered a state-of-the-art 3D imaging technique in TAVR which enhances procedural accuracy and patient safety, further advancing the field of minimally invasive heart valve procedures. Dr. Tang is part of a multidisciplinary cardiovascular care program involving cardiologists, cardiac surgeons, vascular surgeons, radiologists, and allied health professionals in the comprehensive diagnosis and management of heart valve diseases employing leading-edge technologies in a patient-centered environment. As part of the Medical Center's valve disease treatment services, Dr. Tang works closely with regional primary care physicians, internists and cardiologists in the timely access and outstanding care of patients with valvular heart disease, benefiting the residents of northern metropolitan New York City, Westchester and the Lower Hudson Valley.
Select Publications and Presentations
- Tang G, Abu Saleh, WK, Ahmad H, et al. “Expansion of iliofemoral access to <5 mm with recollapsible sheath in high risk TAVR patients is feasible with zero complication” Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, 2015.
- Tang G, Ahmad H, Cohen M, et al. “Awake PCI + TAVI in a very large annulus with self-expanding valve made simple using the “cusp overlap” rule”, PCR London Valves Annual Meeting, 2015.
- Tang G, Michev I, Ahmad H, et al. “Fluoro-guided TAVI with only one-shot contrast: a new technique to minimise dye-induced renal injury”, PCR London Valves Annual Meeting, 2015.
- Tang G, Ahmad H, Cohen M, et al. “How low can you go? <4 mm transfemoral TAVI with extreme thrombocytopenia”, PCR London Valves Annual Meeting, 2015.
- Tang G, Ahmad H, Cohen M, et al. “100% control in tricuspid valve-in-valve replacement using valve delivery catheter sizing and fine tuning”, PCR London Valves Annual Meeting, 2015.
- Tang G, Kai M, Malekan R, et al. “Trifurcated graft replacement of the aortic arch: state of the art” Journal of Thoracic and Cardiovascular Surgery. 2015;149(2 Suppl):S55-8.
- Tang G, Lansman S, Panza JA. ”Beyond PARTNER: appraising the evolving trends and outcomes in transcatheter aortic valve replacement” Cardiology in Review. 2015;23(1):1-10.
- Tang G, Carroll C, Bocchino V, et al. “The concept of ‘effective implant area’: a simple method beyond annular sizing to optimize valve selection and outcomes in transcatheter aortic valve replacement”, American Heart Association (AHA) Annual Scientific Session, 2014.
- Kai M, Tang G, Malekan R, et al. “Veno-artierial ECMO for right heart failure complication LVAD", Journal of Thoracic Cardiovascular Surgery. 2014;147(3):e31-3.
- Tang G, Shah A, Cohen M, et al. “Preoperative identification of aortic root calcium landmark on 3D CT image on M2S imaging software optimizes valve deployment in TAVI”, PCR London Valves Annual Meeting, 2013.
- Tang G, Spielvogel D, Lansman S. “Hypothermia alone may not be enough for cerebral protection in aortic arch surgery”, Texas Heart Institute Journal. 2013;40:564-5.
- Tang G, Malekan R, Kai M, et al. “Peripheral veno-arterial ECMO improves survival in myocardial infarction with cardiogenic shock”, Journal of Thoracic Cardiovascular Surgery. 2013;145:e32-3.
- Tang G, Malekan R, Yu CJ, et al. “Surgery for acute type A aortic dissection in octogenarians is justified”, Journal of Thoracic Cardiovascular Surgery. 2013:145:S186-90.
- Tang G, Lansman SL, Cohen M, et al. “Transcatheter Aortic Valve Replacement: Current Developments, Ongoing Issues, Future Outlook”, Cardiology in Review. 2013;21:55-76.
- Tang G, Osten M, Horlick E, et al. “Percutaneous aortic valve – the Canadian Experience: Present and Future Perspectives” in Navia JL, Al-Ruzzeh S (ed) Percutaneous Valve Technology: Present and Future. New York: Nova Science Publishers, Inc, 2012.
- Tang G, Maganti M, David T, et al. “Effect of prior valve type on mortality in reoperative valve surgery”, Annals of Thoracic Surgery. 2007;83:938-45.
- Singh S, Tang G, Maganti M, et al. “Improved survival with tricuspid valve repair versus replacement for organic tricuspid disease”, Annals of Thoracic Surgery. 2006;82:1735-41.
- Tang G, David T, Singh S, et al. “Tricuspid valve repair with an annuloplasty ring results in improved long-term outcomes", Circulation. 2006;114:577-81.